Medical Policy and Coding Updates - March 2025
Summary
Premera's March 2025 update changes adalimumab and pegfilgrastim preferences, with Humira (AbbVie) moving from a preferred to a non-preferred adalimumab product effective July 1, 2025. It also adds new Parkinson's disease and seizure drug policies effective March 1, 2025, and lists code 92972 as now requiring review for investigational, while several SARS-CoV-2 serology codes and code 25448 no longer require review.
Get alerts when payers change rules like this one
We check Premera Blue Cross and other payers every day and email you when a change matches your specialty and state.